Iwamoto K, Watanabe J
J Pharm Pharmacol. 1985 Nov;37(11):826-8. doi: 10.1111/j.2042-7158.1985.tb04979.x.
Gastrointestinal first-pass elimination of propranolol and the effect of dose (1.0, 2.5, 5.0 and 10.0 mg kg-1) on its systemic availability were studied in male Wistar rats which received the drug intravenously, orally or intraportally. The plasma elimination half-life was not altered either by the route of administration or the dose. There was no gastrointestinal first-pass metabolism of propranolol, since the same systemic availability was obtained after oral and intraportal administration. Hepatic clearance was estimated to be constant at any dose. In contrast, the hepatic intrinsic clearance was found to be largely dependent on the portal dose.
在接受静脉注射、口服或门静脉注射给药的雄性Wistar大鼠中,研究了普萘洛尔的胃肠道首过消除以及剂量(1.0、2.5、5.0和10.0mg/kg)对其全身可用性的影响。血浆消除半衰期不受给药途径或剂量的影响。由于口服和门静脉注射给药后获得相同的全身可用性,因此普萘洛尔不存在胃肠道首过代谢。在任何剂量下,肝脏清除率估计是恒定的。相比之下,发现肝脏内在清除率很大程度上取决于门静脉剂量。